Coherus Biosciences | CHRS - Umsatzkosten

Aktienkurs
1.52
Täglich Wechseln
-0.09 -5.59%
Monatlich
-6.17%
Jährlich
47.57%
Q1 Prognose
1.47




Umsatzkosten Veränderung Datum
AbbVie USD 4.55B 757M 2025-12
Acadia Pharmaceuticals USD 26.22M 4.58M 2025-12
Akebia Therapeutics USD 10.34M 441K 2025-12
ALKERMES USD 46.21M 5.38M 2025-12
Alnylam Pharmaceuticals USD 267.72M 67.57M 2025-12
Amarin USD 26.05M 1.41M 2025-12
Amgen USD 1.79B 128M 2025-12
Baxter International USD 2.4B 512M 2025-12
Biogen USD 810.1M 205.1M 2025-09
BioMarin Pharmaceutical USD 161.56M 16.62M 2025-12
Bristol-Myers Squibb USD 4.92B 657M 2025-12
Coherus Biosciences USD 4.04M 324K 2025-12
Eli Lilly USD 3.37B 363.7M 2025-12
Fujifilm JPY 509.85B 19.73B 2025-12
Gilead Sciences USD 1.62B 50M 2025-12
Ironwood Pharmaceuticals USD 29.83M 560K 2024-09
Merck USD 3.32B 531M 2025-12
Myriad Genetics USD 63M 1.1M 2025-12
Pacira USD 54.62M 6.02M 2025-12
Perrigo USD 747.4M 81.2M 2025-12
Pfizer USD 6.29B 2.12B 2025-12
PTC Therapeutics USD 16.3M 7.02M 2025-12
Regeneron Pharmaceuticals USD 584.6M 63M 2025-12
Sarepta Therapeutics USD 399.38M 247.93M 2025-12
Teva Pharmaceutical Industries USD 2.06B 120M 2025-12
Vertex Pharmaceuticals USD 466M 51.2M 2025-12
Xencor USD 61.66M 50.95M 2025-06
Zoetis USD 743M 60M 2025-12